Cargando…

Infectivity versus fatality of SARS-CoV-2 mutations and influenza

OBJECTIVES: Because of the spread of the Omicron variant, many countries have experienced COVID-19 case numbers unseen since the start of the pandemic. We aimed to compare the epidemiological characteristics of Omicron with previous variants and different strains of influenza to provide context for...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Ling, Jing, Shuanglin, Zhang, Kai, Milne, Russell, Wang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107628/
https://www.ncbi.nlm.nih.gov/pubmed/35584743
http://dx.doi.org/10.1016/j.ijid.2022.05.031
_version_ 1784708523499716608
author Xue, Ling
Jing, Shuanglin
Zhang, Kai
Milne, Russell
Wang, Hao
author_facet Xue, Ling
Jing, Shuanglin
Zhang, Kai
Milne, Russell
Wang, Hao
author_sort Xue, Ling
collection PubMed
description OBJECTIVES: Because of the spread of the Omicron variant, many countries have experienced COVID-19 case numbers unseen since the start of the pandemic. We aimed to compare the epidemiological characteristics of Omicron with previous variants and different strains of influenza to provide context for public health responses. METHODS: We developed transmission models for SARS-CoV-2 variants and influenza, in which transmission, death, and vaccination rates were taken to be time-varying. We fit our model based on publicly available data in South Africa, the United States, and Canada. We used this model to evaluate the relative transmissibility and mortality of Omicron compared with previous variants and influenza. RESULTS: We found that Omicron is more transmissible and less fatal than both seasonal and 2009 H1N1 influenza and the Delta variant; these characteristics make Omicron epidemiologically more similar to influenza than it is to Delta. We estimate that as of February 7, 2022, booster doses have prevented [Formula: see text] and [Formula: see text] Omicron infections in the United States and Canada, respectively. CONCLUSION: Our findings indicate that the high infectivity of Omicron will keep COVID-19 endemic, similar to influenza. However, because of Omicron's lower fatality rate, our work suggests that human populations living with SARS-CoV-2 are most likely.
format Online
Article
Text
id pubmed-9107628
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-91076282022-05-16 Infectivity versus fatality of SARS-CoV-2 mutations and influenza Xue, Ling Jing, Shuanglin Zhang, Kai Milne, Russell Wang, Hao Int J Infect Dis Article OBJECTIVES: Because of the spread of the Omicron variant, many countries have experienced COVID-19 case numbers unseen since the start of the pandemic. We aimed to compare the epidemiological characteristics of Omicron with previous variants and different strains of influenza to provide context for public health responses. METHODS: We developed transmission models for SARS-CoV-2 variants and influenza, in which transmission, death, and vaccination rates were taken to be time-varying. We fit our model based on publicly available data in South Africa, the United States, and Canada. We used this model to evaluate the relative transmissibility and mortality of Omicron compared with previous variants and influenza. RESULTS: We found that Omicron is more transmissible and less fatal than both seasonal and 2009 H1N1 influenza and the Delta variant; these characteristics make Omicron epidemiologically more similar to influenza than it is to Delta. We estimate that as of February 7, 2022, booster doses have prevented [Formula: see text] and [Formula: see text] Omicron infections in the United States and Canada, respectively. CONCLUSION: Our findings indicate that the high infectivity of Omicron will keep COVID-19 endemic, similar to influenza. However, because of Omicron's lower fatality rate, our work suggests that human populations living with SARS-CoV-2 are most likely. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-08 2022-05-15 /pmc/articles/PMC9107628/ /pubmed/35584743 http://dx.doi.org/10.1016/j.ijid.2022.05.031 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Xue, Ling
Jing, Shuanglin
Zhang, Kai
Milne, Russell
Wang, Hao
Infectivity versus fatality of SARS-CoV-2 mutations and influenza
title Infectivity versus fatality of SARS-CoV-2 mutations and influenza
title_full Infectivity versus fatality of SARS-CoV-2 mutations and influenza
title_fullStr Infectivity versus fatality of SARS-CoV-2 mutations and influenza
title_full_unstemmed Infectivity versus fatality of SARS-CoV-2 mutations and influenza
title_short Infectivity versus fatality of SARS-CoV-2 mutations and influenza
title_sort infectivity versus fatality of sars-cov-2 mutations and influenza
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107628/
https://www.ncbi.nlm.nih.gov/pubmed/35584743
http://dx.doi.org/10.1016/j.ijid.2022.05.031
work_keys_str_mv AT xueling infectivityversusfatalityofsarscov2mutationsandinfluenza
AT jingshuanglin infectivityversusfatalityofsarscov2mutationsandinfluenza
AT zhangkai infectivityversusfatalityofsarscov2mutationsandinfluenza
AT milnerussell infectivityversusfatalityofsarscov2mutationsandinfluenza
AT wanghao infectivityversusfatalityofsarscov2mutationsandinfluenza